Coherus BioSciences (CHRS) Stock Forecast & Price Target

→ IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad)

$2.16

+0.01 (+0.47%)

(As of 10:09 AM ET)

Coherus BioSciences Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings

Analysts' Consensus Price Target

$9.29
329.89% Upside

High Forecast	$12.00
Average Forecast	$9.29
Low Forecast	$6.00

Type	Current Forecast 4/19/23 to 4/18/24	1 Month Ago 3/20/23 to 3/19/24	3 Months Ago 1/19/23 to 1/19/24	1 Year Ago 4/19/22 to 4/19/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.29	$9.75	$11.89	$16.50
Predicted Upside	329.89% Upside	169.82% Upside	228.30% Upside	136.45% Upside

Get Coherus BioSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Ad Birch Gold

IRS Loophole Gives Americans An Escape From Inflation

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

Request your info kit on gold now

CHRS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CHRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coherus BioSciences Stock vs. The Competition

Type	Coherus BioSciences	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	331.89% Upside	934.34% Upside	12.27% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
3/20/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$13.00 ➝ $11.00	+348.98%
1/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$11.00 ➝ $9.00	+275.00%
1/23/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$12.00 ➝ $8.00	+210.08%
11/8/2023	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
10/23/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$8.00 ➝ $7.00	+112.12%
10/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$7.00 ➝ $6.00	+59.57%
7/24/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00	+179.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:29 AM ET.

CHRS Price Target - Frequently Asked Questions

What is Coherus BioSciences's consensus rating and price target?: According to the issued ratings of 6 analysts in the last year, the consensus rating for Coherus BioSciences stock is Moderate Buy based on the current 1 hold rating and 5 buy ratings for CHRS. The average twelve-month price prediction for Coherus BioSciences is $9.29 with a high price target of $12.00 and a low price target of $6.00. Learn more on CHRS's analyst rating history.
Do Wall Street analysts like Coherus BioSciences more than its competitors?: Analysts like Coherus BioSciences more than other Medical companies. The consensus rating score for Coherus BioSciences is 2.83 while the average consensus rating score for medical companies is 2.68. Learn more on how CHRS compares to other companies.
Does Coherus BioSciences's stock price have much upside?: According to analysts, Coherus BioSciences's stock has a predicted upside of 185.79% based on their 12-month stock forecasts.

What analysts cover Coherus BioSciences?: Coherus BioSciences has been rated by HC Wainwright, Robert W. Baird, and Truist Financial in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:CHRS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Coherus BioSciences (CHRS) Stock Forecast & Price Target

Coherus BioSciences Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

CHRS Analyst Ratings By Month

CHRS Price Targets by Month

Coherus BioSciences Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

CHRS Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info